Pricing Log in Create free account

Monopar Therapeutics Inc. (MNPR) vs REGENXBIO Inc. (RGNX)

Monopar Therapeutics Inc. and REGENXBIO Inc. are both Biotechnology companies. Monopar Therapeutics Inc. and REGENXBIO Inc. are of similar size ($481.9M and $472.7M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −112.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Monopar Therapeutics Inc. leads on 10 and REGENXBIO Inc. on 1.

Valuation

Metric MNPR RGNX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 2.10 9.71
P/B 4.52 5.10 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 1.53 9.21
Earnings yield (3.13%) (54.69%) (33.15%)
Free cash flow yield (2.06%) (68.21%) (25.50%)

Profitability

Metric MNPR RGNX Biotechnology median
Gross margin — 86.38% 65.16%
Operating margin 0.00% (94.08%) 0.00%
Net margin 0.00% (112.58%) 0.00%
Free cash flow margin 0.00% (143.09%) 0.00%
Return on equity (19.50%) (137.63%) (56.36%)
Return on assets (18.90%) (40.60%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MNPR RGNX Biotechnology median
Revenue growth (TTM) — 12.00% 6.02%
EPS growth (last fiscal year) 54.99% 18.08% 30.26%
Revenue growth, 5-year CAGR — 1.97% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNPR RGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 33.56 2.86 4.72
Net debt to EBITDA 8.06 1.58 0.96

Dividend

Metric MNPR RGNX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MNPR RGNX Biotechnology median
Market cap 481.93m 472.65m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack